Saving Organs. Saving Lives.
RECENT EVENTS
April 17, 2024
Members of the Vascular Perfusion Solutions team, including CEO Rafael Veraza, engaged in thoughtful discussions at the Biofest Invest event in San Antonio hosted by BiomedSA. It was an opportunity for connecting with members in the community and exploring cutting-edge medical technology through pitch presentations.
April 13, 2024
At the ISHLT 2024 event in Prague, Kristina Andrijauskaite, representing VPS, made waves following her prestigious win of the Research & Immunology Professional Community Award for Excellence at ISHLT 2023. Kristina's poster presentations, including topics such as Extended Hypothermic Cardiac Preservation Using the VP.S ENCORE® Device Leads to Enhanced Cardiac Function in a Pilot Orthotopic Porcine Heart Transplant Study received significant attention. This work showcases VPS' innovative solutions and advancements in cardiac preservation technology, promising enhanced outcomes in heart transplantation.
Vision: Preserving organs on-demand to solve the global organ shortage, currently preserved with ice filled coolers and complex expensive technology.
The VP.S ENCORE® Device, with patents pending, has received a Breakthrough Device Designation from the FDA. The Breakthrough Device Designation is designed to facilitate communications between the company and the FDA to ideally accelerate the device to market.
The VP.S ENCORE® is a device that can be modified to eventually extend the preservation of other organs and vascularized tissue. Future uses include the use of ex vivo therapies, and ideally provide a foundation for organ banking.
The impact in developing the VP.S ENCORE® device promises to be significant once data are gathered to demonstrate that this technology can expand the donor pool, resulting in optimized organ matching with less rejection such as primary graft dysfunction.
The VP.S ENCORE® device has not yet been approved by the FDA
Ease of Use
The VP.S ENCORE® system includes a single-use disposable component that operates with a non-blood, nutrient-rich solution (perfusate) that is available in transplant centers. The system is designed to operate in environments with temperatures up to 40ºC and to withstand passenger aircraft cabin pressures.
In addition, the VP.S ENCORE® device has a rugged design that is easy to transport, and should the device fail for any reason, the device reverts to the standard of care (static cooling).
Portable
The VP.S ENCORE® Device is designed to facilitate transportation with an outer housing the size of carry-on luggage. By comparison, competing technologies that utilize blood as the perfusate are large and cumbersome requiring special transport vehicles.
Left: VP.S ENCORE® Device
Right: Office Copier machine